Entrada Therapeutics TRDA Q2 2025 earnings
Reported August 6, 2025 · Before market open
Revenue$2.0MMiss by $5.9M
EPS-$1.04Miss by $0.18
Revenue estimate$7.8M
EPS estimate-$0.86
Next report
Aug 5, 2026 (In 1 week)Revenue estimate$2.2M
EPS estimate-$1.05
Versus estimates
Revenue
Diluted EPS
Ask the moment Entrada Therapeutics reports.
Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.
Connect your AI
Claude
Questions, answered.
- When did Entrada Therapeutics report Q2 2025 earnings?
- Entrada Therapeutics (TRDA) reported Q2 2025 earnings on August 6, 2025 before market open.
- What were Entrada Therapeutics's Q2 2025 revenue and EPS?
- Entrada Therapeutics reported revenue of $2.0M and eps of $-1.04 for Q2 2025.
- Did Entrada Therapeutics beat estimates in Q2 2025?
- Revenue missed the consensus estimate of $7.8M by $5.9M. EPS missed the consensus estimate of $-0.86 by $0.18.
- How did Entrada Therapeutics's Q2 2025 results compare year-over-year?
- Compared to the same quarter a year prior, revenue declined 97.9% from $94.7M a year earlier.
- Where can I find Entrada Therapeutics's Q2 2025 SEC filings?
- You can read the 10-Q periodic report (0001689375-25-000043) directly on SEC EDGAR. The filing index links above go to sec.gov.